Katherine K. Hsu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katherine K. Hsu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Stephen I. Pelton
Boston Medical Center, Boston, MA 02118, USA
3 shared publications Abbie E. Stevenson
1 shared publicationDaniel S. Shapiro
Maxwell Finland Laboratory for Infectious Diseases, Boston University School of Medicine and Boston Medical Center, Boston, MA 02118, USA
1 shared publicationDemian Christiansen
1 shared publicationDenise O'COnnor
1 shared publication- John Bernardo
Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts
1 shared publication
Latest Publications
- 1 April 2010
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 29 (4) , 289-293
Changing Serotypes Causing Childhood Invasive Pneumococcal Disease
Background: Heptavalent pneumococcal conjugate vaccine (PCV7) was licensed in the United States in February 2000 and distributed in Massachusetts, starting in July 2000 for universal administration to children Streptococcus pneumoniae from normally sterile body fluid. Demographic and clinical data, were collected via follow-up telephone interviews with primary care providers. Incidence rates were derived using Census 2000 denominators. Results: A total of 586 IP cases were reported between October 2001 and September 2007. Among 433 (74%) cases with isolates available for serotyping, 366 (85%) were caused by non-PCV7 serotypes and 67 (15%) were caused by PCV7 serotypes. 19A was the most common cause of any serotype identified episode of IPD (28%). IPD incidence was stable during the 6 study years because, although IPD cases due to PCV7-serotypes decreased, the incidence of non-PCV7 serotype IPD increased from 3.0 cases/100,000 children less than 18 years to a high of 5.3 cases/100,000 during 2005 to 06. Since 2005, ceftriaxone non-susceptible isolates comprised approximately 20% of isolates. There were 8 (1.4%) fatalities from IPD; 5 deaths occurred in children <1 year of age. Conclusions: Non-PCV7 serotype IPD, especially serotype 19A disease, increased during the 2001 to 2007 surveillance period in Massachusetts. The proportion of ceftriaxone non susceptible isolates also increased, particularly since 2005. Ongoing surveillance will be necessary to detect future increases in IPD incidence or antibiotic resistance in Massachusetts children, changes which have important implications for introduction of second generation pneumococcal conjugate vaccines and presumptive antibiotic choices in critically ill children.
- 1 April 2010
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 29 (4) , 289-293
Changing Serotypes Causing Childhood Invasive Pneumococcal Disease
Background: Heptavalent pneumococcal conjugate vaccine (PCV7) was licensed in the United States in February 2000 and distributed in Massachusetts, starting in July 2000 for universal administration to children Streptococcus pneumoniae from normally sterile body fluid. Demographic and clinical data, were collected via follow-up telephone interviews with primary care providers. Incidence rates were derived using Census 2000 denominators. Results: A total of 586 IP cases were reported between October 2001 and September 2007. Among 433 (74%) cases with isolates available for serotyping, 366 (85%) were caused by non-PCV7 serotypes and 67 (15%) were caused by PCV7 serotypes. 19A was the most common cause of any serotype identified episode of IPD (28%). IPD incidence was stable during the 6 study years because, although IPD cases due to PCV7-serotypes decreased, the incidence of non-PCV7 serotype IPD increased from 3.0 cases/100,000 children less than 18 years to a high of 5.3 cases/100,000 during 2005 to 06. Since 2005, ceftriaxone non-susceptible isolates comprised approximately 20% of isolates. There were 8 (1.4%) fatalities from IPD; 5 deaths occurred in children <1 year of age. Conclusions: Non-PCV7 serotype IPD, especially serotype 19A disease, increased during the 2001 to 2007 surveillance period in Massachusetts. The proportion of ceftriaxone non susceptible isolates also increased, particularly since 2005. Ongoing surveillance will be necessary to detect future increases in IPD incidence or antibiotic resistance in Massachusetts children, changes which have important implications for introduction of second generation pneumococcal conjugate vaccines and presumptive antibiotic choices in critically ill children.
- 1 December 2003
- Published by American Medical Association (AMA) in Archives of Pediatrics & Adolescent Medicine
- Vol. 157 (12) , 1227-1231
Self-assessment of Tuberculosis Infection Risk by Urban Adolescents
Research from JAMA Pediatrics — Self-assessment of Tuberculosis Infection Risk by Urban Adolescents
- 1 December 2003
- Published by American Medical Association (AMA) in Archives of Pediatrics & Adolescent Medicine
- Vol. 157 (12) , 1227-1231
Self-assessment of Tuberculosis Infection Risk by Urban Adolescents
Research from JAMA Pediatrics — Self-assessment of Tuberculosis Infection Risk by Urban Adolescents
- 1 October 2003
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 2 (5) , 619-631
Heptavalent pneumococcal conjugate vaccine: current and future impact
Diseases caused by Streptococcus pneumoniae contribute significantly to worldwide morbidity and mortality. S. pneumoniae is now the number one cause of invasive bacterial disease in children in countries where Haemophilus influenzae type b (Hib) disease has been conquered by use of the Hib conjugate vaccine. Licensure of a heptavalent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children less than 5 years old in the USA represents the culmination of more than five decades of pneumococcal vaccine development. This review will: highlight safety, immunogenicity and efficacy studies that led to US Food and Drug Administration approval of this PCV7; summarize data about the incidence of childhood pneumococcal disease in the USA subsequent to licensure; review PCV7 treatment guidelines currently in place in the USA, Canada and Australia; and consider future directions in pneumococcal vaccine research.
- 1 October 2003
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 2 (5) , 619-631
Heptavalent pneumococcal conjugate vaccine: current and future impact
Diseases caused by Streptococcus pneumoniae contribute significantly to worldwide morbidity and mortality. S. pneumoniae is now the number one cause of invasive bacterial disease in children in countries where Haemophilus influenzae type b (Hib) disease has been conquered by use of the Hib conjugate vaccine. Licensure of a heptavalent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children less than 5 years old in the USA represents the culmination of more than five decades of pneumococcal vaccine development. This review will: highlight safety, immunogenicity and efficacy studies that led to US Food and Drug Administration approval of this PCV7; summarize data about the incidence of childhood pneumococcal disease in the USA subsequent to licensure; review PCV7 treatment guidelines currently in place in the USA, Canada and Australia; and consider future directions in pneumococcal vaccine research.
- 30 January 2003
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 45 (1) , 23-27
Detection of group B streptococcal bacteremia in simulated intrapartum antimicrobial prophylaxis
- 30 January 2003
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 45 (1) , 23-27
Detection of group B streptococcal bacteremia in simulated intrapartum antimicrobial prophylaxis
- 1 October 2001
- Published by American Medical Association (AMA) in Archives of Pediatrics & Adolescent Medicine
- Vol. 155 (10) , 1173-1174
Pathological Case of the Month
Case Report from JAMA Pediatrics — Pathological Case of the Month
- 1 October 2001
- Published by American Medical Association (AMA) in Archives of Pediatrics & Adolescent Medicine
- Vol. 155 (10) , 1173-1174
Pathological Case of the Month
Case Report from JAMA Pediatrics — Pathological Case of the Month